Plain-English translation of NCT07803653 on ClinicalTrials.gov ↗ · Source last updated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
United States
Phase
Safety & dosing
Sponsor
Fred Hutchinson Cancer Center
Collaborators
PromiCell Therapeutics, Inc.
Enrollment target
~20 participants
Started
October 2026
Primary completion
October 2030
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Fred Hutch Intake
Fred Hutch/University of Washington Cancer Consortium
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.